| Name | Title | Contact Details |
|---|---|---|
George Francis |
Chief Information Officer | Profile |
Jonathan Waldern |
Chief Technology Officer | Profile |
Spruce is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Our wholly-owned product candidate, tildacerfont, is a CRF1 receptor antagonist currently in late-stage trials in adult patients with classic congenital adrenal hyperplasia (CAH), with a planned Phase 2 trial in pediatric classic CAH. We aim to advance the treatment paradigm for classic CAH with a well-tolerated, non-steroidal approach designed to offer markedly improved disease control and reduced steroid burden for patients. Tildacerfont may also benefit patients with other disorders characterized by elevated levels of or hyperresponsiveness to adrenocorticotropic hormone (ACTH), a hormone involved in the production of cortisol, including a rare form of polycystic ovary syndrome (PCOS).
JUMPCODE Genomic`s patented technology unlocks the power of Next Generation Sequencing by improving sensitivity, reducing costs, simplifying workflows and removing bias. Researchers around the world are using our CRISPRClean technology in the fields of infectious disease, oncology, consumer genomics, food science and basic research.
Scioto Biosciences is a preclinical stage biotech company dedicated to innovative research and discovery in the field of microbiome therapeutics.
AmerisourceBergen Drug Corporation is a Wayne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lifeprint is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.